Skip to main content

Table 4 Improved endurance performance and disease activity after 12 weeks of endurance exercise in myositis patients.

From: Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis

Patient Group MMT
0 to 80
HAQ
0.00 to 3.00
s-CPK
μcat/l
Physician's
global disease activity
VAS
0 to 100
Patient's
global disease activity
VAS
0 to 100
Mitax
0.00 to 1.00
Cycling
time minutes
  EG/CG 0w 12w 0w 12w 0w 12w 0w 12w 0w 12w 0w 12w 0w 12w
A† EG 79 79 0.00 0.25 6.2 1.2 5 0 3 1 0.05 0.00 18 31‡
B† EG 70 75 0.50 0.38 2.2 1.9 4 0 72 5 0.11 0.07 8 55‡
C† EG 75 77 0.25 0.00 1.8 1.3 0 0 9 0 0.24 0.19 15 37‡
D† EG 76 80 0.38 0.00 4.2 2.3 0 0 0 9 0.10 0.06 25 30‡
E EG 42 57‡ NA 1.63 6.8 5.2 NA 3 NA 43 0.02 0.22 13 20‡
F† EG 76 75 0.50 0.50 NA NA 14 0 15 0 0.16 0.04 15 50‡
G EG 71 76 0.38 0.38 1.5 2.0 3 0 32 11 0.00 0.00 10 15‡
H EG 76 78 0.50 0.50 1.0 1.1 11 7 54 53 0.06 0.02 20 40‡
I† EG 77 77 1.38 0.63 1.3 1.3 10 3 24 13 0.11 0.02 15 25‡
J CG 77 77 0.38 0.63 1.6 3.1 0 0 44 26 0.19 0.11 9 10
K† CG 72 74 0.38 0.00 1.8 1.8 1 0 13 5 0.06 0.10 15 15
L CG 66 73 0.50 0.13 1.3 1.2 0 0 77 52 0.09 0.21 15 15
M CG 75 70 0.50 0.38 3.7 1.9 3 5 20 44 0.14 0.13 20 20
N CG 57 75‡ 1.75 2.00 NA NA NA 5 59 69 NA 0.24 8 8
O CG 75 72 0.63 0.88 1.2 1.6 10 6 39 59 0.13 NA 15 19‡
  1. Individual results in myositis core set measures for disease activity and endurance performance (cycling time) before and after training (exercise group) or in the non-exercising control group. Data are analyzed by criteria for minimal clinical improvement set for patients with polymyositis and dermatomyositis [32]. 0 w, baseline assessment; 12 w, follow-up assessment; CG, control group (n = 6); EG, exercise group (n = 9); HAQ, health assessment questionnaire; MITAX, myositis intention to treat activity index; MMT, manual muscle test; NA, not assessed; s-CPK, creatine phosphokinase, (normal values <2.5 μcat/l in women, <3.0 μcat/l in men). Classification of improvement in disease activity measures: †, improved compared to baseline by ≥20% in ≥50% of measures with no more than two worsened by ≥25%, which cannot include MMT. ‡, improved muscle function (MMT/cycling time) compared to baseline by ≥ 20%.